JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
- 17 July 2008
- journal article
- review article
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 19 (4), 385-393
- https://doi.org/10.1016/j.semcdb.2008.07.002
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domainProceedings of the National Academy of Sciences, 2001
- Crystallographic Evidence for Preformed Dimers of Erythropoietin Receptor Before Ligand ActivationScience, 1999
- Erythropoietin Receptor Activation by a Ligand-Induced Conformation ChangeScience, 1999
- CYTOKINE RECEPTOR SIGNAL TRANSDUCTION AND THE CONTROL OF HEMATOPOIETIC CELL DEVELOPMENTAnnual Review of Cell and Developmental Biology, 1996
- Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.Proceedings of the National Academy of Sciences, 1994
- Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cellsNature, 1994
- Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2Nature, 1994
- A protein tyrosine kinase in the interferon αβ signaling pathwayCell, 1992
- Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.Molecular and Cellular Biology, 1991
- Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction.Proceedings of the National Academy of Sciences, 1989